Advancing CAR T for Drug-Free Remission in Autoimmune Disease with Kyverna Therapeutics’ Dr. Naji Gehchan

We love to hear from our listeners. Send us a message.In episode 130 of Cell & Gene: The Podcast, Dr. Naji Gehchan, Chief Medical and Development Officer at Kyverna Therapeutics, joins Host Erin Harris to outline the company’s mission to apply CAR T-cell therapy beyond oncology to treat severe autoimmune diseases, highlighting promising Phase 2 data from its investigational therapy, Miv-cel, in stiff person syndrome (SPS). Dr. Gehchan explains that Miv-cel works by deeply depleting pathogenic B cells and enabling a broad immune reset, differentiating it from conventional therapies that require ongoing management. As Kyverna advances a rolling BLA submission, Dr. Gehchan positions this milestone as potentially historic, both for SPS patients and for the broader cell therapy field, signaling an inflection point where CAR T could transform autoimmune disease care in the same way it has oncology.Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn